A
18.79
-0.82 (-4.18%)
| Previous Close | 19.61 |
| Open | 18.87 |
| Volume | 3,641,493 |
| Avg. Volume (3M) | 1,925,263 |
| Market Cap | 2,461,358,592 |
| Price / Sales | 2.98 |
| Price / Book | 10.24 |
| 52 Weeks Range | |
| Earnings Date | 5 May 2025 - 9 May 2025 |
| Profit Margin | -25.33% |
| Operating Margin (TTM) | -12.31% |
| Diluted EPS (TTM) | -1.60 |
| Quarterly Revenue Growth (YOY) | 45.20% |
| Total Debt/Equity (MRQ) | 205.56% |
| Current Ratio (MRQ) | 4.25 |
| Operating Cash Flow (TTM) | -87.87 M |
| Levered Free Cash Flow (TTM) | -35.70 M |
| Return on Assets (TTM) | -12.32% |
| Return on Equity (TTM) | -93.55% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Apellis Pharmaceuticals, Inc. | Bearish | Bearish |
AIStockmoo Score
-0.3
| Analyst Consensus | 1.0 |
| Insider Activity | NA |
| Price Volatility | 3.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | -2.5 |
| Average | -0.25 |
|
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 13.85% |
| % Held by Institutions | 103.22% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 57.00 (HC Wainwright & Co., 203.35%) | Buy |
| Median | 31.50 (67.64%) | |
| Low | 25.00 (RBC Capital, 33.05%) | Hold |
| Average | 38.00 (102.24%) | |
| Total | 2 Buy, 4 Hold | |
| Avg. Price @ Call | 24.05 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Scotiabank | 02 Apr 2025 | 31.00 (64.98%) | Hold | 23.00 |
| JP Morgan | 04 Mar 2025 | 54.00 (187.39%) | Buy | 25.05 |
| Goldman Sachs | 03 Mar 2025 | 32.00 (70.30%) | Hold | 24.06 |
| HC Wainwright & Co. | 03 Mar 2025 | 57.00 (203.35%) | Buy | 24.06 |
| 13 Feb 2025 | 57.00 (203.35%) | Buy | 27.46 | |
| RBC Capital | 03 Mar 2025 | 25.00 (33.05%) | Hold | 24.06 |
| 29 Jan 2025 | 26.00 (38.37%) | Hold | 29.47 | |
| Wedbush | 03 Mar 2025 | 29.00 (54.34%) | Hold | 24.06 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 01 Apr 2025 | Announcement | Apellis Announces FDA Acceptance and Priority Review of the Supplemental New Drug Application for EMPAVELI® (pegcetacoplan) for C3G and Primary IC-MPGN |
| 28 Feb 2025 | Announcement | Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results |
| 24 Feb 2025 | Announcement | Apellis Pharmaceuticals to Present at the TD Cowen 45th Annual Health Care Conference |
| 20 Feb 2025 | Announcement | Apellis and Sobi Announce EMA Validation of Indication Extension Application for Aspaveli® (pegcetacoplan) for C3G and Primary IC-MPGN |
| 14 Feb 2025 | Announcement | Apellis Pharmaceuticals to Host Conference Call on February 28, 2025, to Discuss Fourth Quarter and Full Year 2024 Financial Results |
| 04 Feb 2025 | Announcement | Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 27 Jan 2025 | Announcement | Apellis Receives Approval of SYFOVRE® (pegcetacoplan) in Australia for Geographic Atrophy (GA) |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |